Global Markets Update: Oil Supply Resiliency, European Corporate Shifts, and Geopolitical Trade Tensions
· thestockmarketwatch.com
Novartis (NVS) faced significant selling pressure today after its experimental drug, pelacarsen, failed to meet primary endpoints in the Lp(a)HORIZON trial.
Key Takeaways
Novartis (NVS) shares tumbled nearly 4% following the failure of its high-stakes cardiovascular drug pelacarsen in a Phase III trial, marking the...